Exchange: NASDAQ·Updated 10:22 AM EDT
News
all
press releases
Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates
Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway, today announced financial results for the quarter ended June 30, 2026, and highlighted recent corporate accomplishments and 2026...
Business Wire
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeths Board of Directors granted two new employees options to purchase an aggregate of 25,500 shares of the Companys common stock in connection with their employment (collectively, the Option Awards). The...
Business Wire
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeths Board of Directors granted six new employees options to purchase an aggregate of 180,350 shares of the Companys common stock in connection with their employment (collectively, the Option Awards). The...
Business Wire
Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that it has changed its corporate name to Faeth Therapeutics, Inc. (the Company). The Companys common stock is expected to begin trading on the Nasdaq Capital Market under the new ticker symbol FTH on June 16, 2026, and the Company has...
Business Wire
<
1
>

Advertisement|Remove ads.